The Role of the Endocrine Glands in Ketosis—I. The Ketosis of Fasting

Por Amatruda, Thomas T., Engel, Frank L.
Publicado em 1959

THE ROLE OF THE ENDOCRINE GLANDS IN KETOSIS. II. KETONEMIA FOLLOWING INSULIN HYPOGLYCEMIA

Por Amatruda, Thomas T., Chase, Joan W., Engel, Frank L.
Publicado em 1962

Is Age ≥ 70 Years an Important Predictor of Adverse Events Among Patients Enrolled in Metastatic Melanoma Trials? Findings from Pooled Analyses of Therapeutic Trials

Por Jatoi, Aminah, Allred, Jacob B., Suman, Vera J., Creagan, Edward T., Croghan, Gary A., Amatruda, Thomas, Markovic, Svetomir N.
Publicado em 2012

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens...

Por Dillman, Robert O, McClay, Edward, Amatruda, Thomas, Semeniuk, George, Haskins, Clark, Weber, Robert, Burtzo, David, DePriest, Carol, Carbonell, Denysha, Cornforth, Andrew
Publicado no J Immunother Cancer (2015)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Por Kaufman, Howard L., Amatruda, Thomas, Reid, Tony, Gonzalez, Rene, Glaspy, John, Whitman, Eric, Harrington, Kevin, Nemunaitis, John, Zloza, Andrew, Wolf, Michael, Senzer, Neil N.
Publicado no J Immunother Cancer (2016)

Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at...

Por Dillman, Robert O., McClay, Edward F., Barth, Neil M., Amatruda, Thomas T., Schwartzberg, Lee S., Mahdavi, Khosrow, de Leon, Cristina, Ellis, Robin E., DePriest, Carol
Publicado no Cancer Biother Radiopharm (2015)

Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients with Unresectable Stage IV Melanoma – A North Central Cancer Treatment Group (NCCTG) Study, N0...

Por Perez, Domingo G., Suman, Vera J., Fitch, Tom R., Amatruda, Thomas, Morton, Roscoe F., Jilani, Shamim Z., Constantinou, Costas L., Egner, James R., Kottschade, Lisa A., Markovic, Svetomir N.
Publicado em 2009

Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients

Por Koyanagi, Kazuo, O’Day, Steven J., Gonzalez, Rene, Lewis, Karl, Robinson, William A., Amatruda, Thomas T., Kuo, Christine, Wang, He-Jing, Milford, Robert, Morton, Donald L., Hoon, Dave S.B.
Publicado em 2006

Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial

Por Koyanagi, Kazuo, O’Day, Steven J., Gonzalez, Rene, Lewis, Karl, Robinson, William A., Amatruda, Thomas T., Wang, He-Jing, Elashoff, Robert M., Takeuchi, Hiroya, Umetani, Naoyuki, Hoon, Dave S.B.
Publicado em 2005

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma- A North Central Cancer Treatment Group Study, N057E

Por Kottschade, Lisa A, Suman, Vera J., Amatruda, Thomas, McWilliams, Robert R., Mattar, Bassam I., Nikcevich, Daniel A, Behrens, Robert, Fitch, Tom R, Jaslowski, Anthony J, Markovic, Svetomir N
Publicado em 2010

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

Por Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Publicado no Ann Surg Oncol (2016)

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unres...

Por Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Publicado no Head Neck (2016)

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melan...

Por Andtbacka, Robert HI, Collichio, Frances A, Amatruda, Thomas, Senzer, Neil, Chesney, Jason, Delman, Keith, Spitler, Lynn, Puzanov, Igor, Agarwala, Sanjiv, Milhem, Mohammed, Harrington, Kevin, Middleton, Mark, Li, Ai, Shilkrut, Mark, Coffin, Robert, Kaufman, Howard
Publicado no J Immunother Cancer (2014)

A randomized phase II study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer...

Por Kottschade, Lisa A., Suman, Vera J., Perez, Domingo G., McWilliams, Robert R., Kaur, Judith S., Amatruda, Thomas T., Geoffroy, Francois J., Gross, Howard M., Cohen, Peter A., Jaslowski, Anthony J., Kosel, Matthew L., Markovic, Svetomir N.
Publicado em 2012

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Por Koyanagi, Kazuo, O’Day, Steven J., Boasberg, Peter, Atkins, Michael B., Wang, He-Jing, Gonzalez, Rene, Lewis, Karl, Thompson, John A., Anderson, Clay M., Lutzky, Jose, Amatruda, Thomas T., Hersh, Evan, Richards, Jon, Weber, Jeffrey S., Hoon, Dave S. B.
Publicado em 2010